Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells

Pharmazie

Volumn 64, Issue 10, 2009, Pages 660-665

  Xu, Hong Bin ^a   Li, Ling ^a   Liu, Guo Qing ^b  

^a TONGJI UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; GUGGULSTERONE; RHODAMINE 123; VERAPAMIL; ANTINEOPLASTIC ANTIBIOTIC; CALCIUM CHANNEL BLOCKING AGENT; FLUORESCENT DYE; PREGNA 4,17 DIENE 3,16 DIONE; PREGNA-4,17-DIENE-3,16-DIONE; PREGNANE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL STRAIN K 562; CHEMICAL STRUCTURE; COMMIPHORA; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; P-GLYCOPROTEINS; PREGNENEDIONES; RHODAMINE 123; VERAPAMIL;

EID: 74949111437     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2009.9619     Document Type: Article

References (23)

1. Agrawal H, Kaul N, Paradkar AR, Mahadik KR (2004) HPTLC method for guggulsterone. I. Quantitative determination of E- and Z-guggulsteronein herbal extract and pharmaceutical dosage form. J Pharm Biomed Anal 36: 33-41.
2. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64: 573-582.
3. Dale IL, Tuffley W, Callaghan R Holmes JA, Martin K, Luscombe M, Mistry P, Ryder H, Stewart AJ, Charlton P, Twentyman PR, Bevan P (1998) Reversal of P-glycoprotein -mediated multidrug resistance by XR9051, a novel diketopiperazine derivative. Br J Cancer 78: 885-892.
4. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42: 155-199.
5. Galski H, SivanH, Lazarovici P, NaglerA(2006) In vitro and in vivo reversal of MDR1- mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk Res 30: 1151-1158.
6. Gong J, Traganos F, Darzynkiewicz Z (1994)A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314-319.
7. Gottesman MM,Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427.
8. Green LJ, Marder P, Slapak CA (2001) Modulation by LY335979 of Pglycoprotein function in multidrug-resistant cell lines and human natural killer cells. Biochem Pharmacol 61: 1393-1399.
9. Gros P, Ben Neriah YB, Croop JM, Housman DE (1986) Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-731.
10. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210.
11. Ji BS, He L, Liu GQ (2005) Modulation of P-glycoprotein function by amlodipine derivatives in brain microvessel endothelial cells of rats. Acta Pharmacol Sin 26: 166-170.
12. Krishna R, Mayer LD (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11: 265-283.
13. Lehnert M, de Giuli R, Twentyman PR (1996) Sensitive and rapid bioassay for analysis of P-glycoprotein-inhibiting activity of chemosensitizers in patient serum. Clin Cancer Res 2: 403-410.
14. Limtrakul P, Anuchapreeda S, Buddhasukh D (2004) Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4: 13.
15. Ling V (1997) Multidrug resistance: molecular mechanism and clinical relevance. Cancer Chemother Pharmacol 40 (Suppl): S3-S8.
16. Liu CJ, Liu JG, Yu TC (2006) Tanshinone microemulsion reverses multidrug resistance of tumor. Chin J Clin Rehabil 10: 181-184.
17. Nabekura T, Yamaki T, Ueno K, Kitagawa S (2008) Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 369: 363-368.
18. Newman MJ, Rodarte JC, Benbatoul KD Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD (2000) Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60: 2964-2972.
19. Qi J, Yang CZ, Wang CY Wang SB, Yang M, Wang JH (2002) Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance. Acta Pharmacol Sin 23: 544-550.
20. Sinal CJ, Gonzalez FJ (2002) Guggulsterone: an old approach to a new problem. Trends Endocrinol Metab 13: 275-276.
21. Sparreboom A, Planting AS, Jewell RC an der BurgME, van der Gaast A, de Bruijn P, Loos WJ, Nooter K, Chandler LH, Paul EM, Wissel PS, Verweij J (1999) Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1P-glycoprotein. Anticancer Drugs 10: 719-728.
22. Urizar NL, Moore DD (2003) Gugulipid: a natural cholesterol-lowering agent. Annu Rev Nutr 23: 303-313.
23. Yoshimura A, Shudo N, Ikeda SI, Ichikawa M, Sumizawa T, Akiyama SI (1990) Novel screening method for agents that overcome classical multidrug resistance in human cell line. Cancer Lett 50: 45-51.